Medshine Discovery Inc. has patented selenium-containing compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has disclosed pyrimidopyrazine compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
A recent Canwell Biotech Ltd. patent details the discovery of methionine aminopeptidase-2 (MetAP2) inhibitors reported to be useful for the treatment of cancer, diabetes, obesity, rheumatoid arthritis and psoriasis.
Yiteng Pharmaceutical Industry Taizhou Co. Ltd. has described cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Xi'an Xintong Medicine Research Co. Ltd. has synthesized 1,3-benzodioxolane-containing compounds acting as dual Bruton tyrosine kinase (BTK) and tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of rheumatoid arthritis and B-cell lymphoma.
RNA binding fox-1 homologue 1 (RBFOX1) is a splicing factor that regulates alternative splicing and modulates the expression of several genes involved in brain development, and it is among the top identified loci related to psychiatric disorders.
Rational drug design based on EPI-X4, endogenous antagonist of C-X-C motif chemokine receptor (CXCR4), led to the identification of optimized analogues named JMF-01 to JMF-07, which demonstrated increased antagonistic activity.
Researchers from Astellas Pharma Inc. presented preclinical data for the novel 5-HT5A receptor antagonist, ASP-5736, being developed for the treatment of fragile X syndrome (FXS).
RSS
